Partially randomized, non-blinded trial of DNA and MVA therapeutic vaccines based on hepatitis B virus surface protein for chronic HBV infection.

Partially randomized, non-blinded trial of DNA and MVA therapeutic vaccines based on hepatitis B virus surface protein for chronic HBV infection.

BACKGROUND: Chronic HBV infects 350 million people causing cancer and liver failure. We aimed to assess the safety and efficacy of plasmid DNA (pSG2.HBs) vaccine, followed by recombinant modified vaccinia virus Ankara (MVA.HBs), encoding the surface antigen of HBV as therapy for chronic HBV. A secon...

Detaylı Bibliyografya
Asıl Yazarlar:	Cavenaugh, J, Awi, D, Mendy, M, Hill, A, Whittle, H, McConkey, S
Materyal Türü:	Journal article
Dil:	English
Baskı/Yayın Bilgisi:	Public Library of Science 2011

Benzer Materyaller

Partially randomized, non-blinded trial of DNA and MVA therapeutic vaccines based on hepatitis B virus surface protein for chronic HBV infection.
Yazar:: James S Cavenaugh, ve diğerleri
Baskı/Yayın Bilgisi: (2011-02-01)

Safety, immunogenicity, and efficacy results of a phase II trial of therapeutic vaccines for chronic HBV in the Gambia.
Yazar:: McConkey, S, ve diğerleri
Baskı/Yayın Bilgisi: (2004)

Therapeutic vaccination against hepatitis B virus using heterolgous prime boost strategy with DNA and modified vaccinia virus ankara vectors
Yazar:: McConkey, S, ve diğerleri
Baskı/Yayın Bilgisi: (2003)

Synergistic DNA-MVA prime-boost vaccination regimes for malaria and tuberculosis.
Yazar:: Gilbert, S, ve diğerleri
Baskı/Yayın Bilgisi: (2006)

Novel oligonucleotide assay detects HBV pre-core and basal core mutations in HBV-infected Gambians
Yazar:: Mendy, M, ve diğerleri
Baskı/Yayın Bilgisi: (2006)

Application of real-time PCR to quantify hepatitis B virus DNA in chronic carriers in The Gambia
Yazar:: Waight Pauline A, ve diğerleri
Baskı/Yayın Bilgisi: (2006-04-01)

DNA/MVA Vaccines for HIV/AIDS
Yazar:: Smita S. Iyer, ve diğerleri
Baskı/Yayın Bilgisi: (2014-02-01)

Changes in viral load and HBsAg and HBeAg status with age in HBV chronic carriers in The Gambia
Yazar:: Crozier Sarah, ve diğerleri
Baskı/Yayın Bilgisi: (2008-04-01)

Development of a DNA-MVA/HIVA vaccine for Kenya.
Yazar:: Hanke, T, ve diğerleri
Baskı/Yayın Bilgisi: (2002)

A randomised, double-blind, controlled vaccine efficacy trial of DNA/MVA ME-TRAP against malaria infection in Gambian adults.
Yazar:: Moorthy, V, ve diğerleri
Baskı/Yayın Bilgisi: (2004)

A randomised, double-blind, controlled vaccine efficacy trial of DNA/MVA ME-TRAP against malaria infection in Gambian adults.
Yazar:: Vasee S Moorthy, ve diğerleri
Baskı/Yayın Bilgisi: (2004-11-01)

A Phase Ia study to assess the safety and immunogenicity of new malaria vaccine candidates ChAd63 CS administered alone and with MVA CS
Yazar:: De Barra, E, ve diğerleri
Baskı/Yayın Bilgisi: (2014)

In situ analysis of hepatitis B virus (HBV) antigen and DNA in HBV-induced hepatocellular carcinoma
Yazar:: Ye Zheng, ve diğerleri
Baskı/Yayın Bilgisi: (2022-01-01)

Host genetic factors and vaccine-induced immunity to HBV infection: haplotype analysis
Yazar:: Ryckman, K, ve diğerleri
Baskı/Yayın Bilgisi: (2010)

Protection of IFNAR (-/-) mice against bluetongue virus serotype 8, by heterologous (DNA/rMVA) and homologous (rMVA/rMVA) vaccination, expressing outer-capsid protein VP2.
Yazar:: Tamara Kusay Jabbar, ve diğerleri
Baskı/Yayın Bilgisi: (2013-01-01)

Immunogenicity and efficacy of DNA/MVA HIV vaccines in rhesus macaque models
Yazar:: Lynette Siv Chea, ve diğerleri
Baskı/Yayın Bilgisi: (2017-10-01)

Hepatitis B Virus (HBV) Subviral Particles as Protective Vaccines and Vaccine Platforms
Yazar:: Joan Kha-Tu Ho, ve diğerleri
Baskı/Yayın Bilgisi: (2020-01-01)

Lack of implementation of Hepatitis B Virus (HBV) vaccination policy in household contacts of HBV carriers in Italy
Yazar:: Scognamiglio Paola, ve diğerleri
Baskı/Yayın Bilgisi: (2009-06-01)

KIR content genotypes associate with carriage of hepatitis B surface antigen, e antigen and HBV viral load in Gambians
Yazar:: Yindom, L, ve diğerleri
Baskı/Yayın Bilgisi: (2017)

A hepatitis B virus-derived peptide combined with HBsAg exerts an anti-HBV effect in an HBV transgenic mouse model as a therapeutic vaccine
Yazar:: Yu-Min Choi, ve diğerleri
Baskı/Yayın Bilgisi: (2023-06-01)

Hepatitis B viral load and risk for liver cirrhosis and hepatocellular carcinoma in The Gambia, West Africa.
Yazar:: Mendy, M, ve diğerleri
Baskı/Yayın Bilgisi: (2010)

Influence of adenovirus and MVA vaccines on the breadth and hierarchy of T cell responses
Yazar:: Rollier, C, ve diğerleri
Baskı/Yayın Bilgisi: (2016)

Therapeutic vaccines in HBV: lessons from HCV
Yazar:: Barnes, E
Baskı/Yayın Bilgisi: (2015)

Host genetic factors and vaccine-induced immunity to HBV infection: haplotype analysis.
Yazar:: Kelli K Ryckman, ve diğerleri
Baskı/Yayın Bilgisi: (2010-08-01)

A phase Ia study to assess the safety and immunogenicity of new malaria vaccine candidates ChAd63 CS administered alone and with MVA CS.
Yazar:: Eoghan de Barra, ve diğerleri
Baskı/Yayın Bilgisi: (2014-01-01)

Application of a novel, rapid, and sensitive oligonucleotide ligation assay for detection of cancer-predicting mutations in the precore and basal core promoter of hepatitis B virus.
Yazar:: Mendy, M, ve diğerleri
Baskı/Yayın Bilgisi: (2008)

P19-58 LB. Comparison of the immunogenicity in humans and rhesus macaques of vaccines consisting of DNA priming and MVA boosting and MVA priming and boosting
Yazar:: Wyatt LS, ve diğerleri
Baskı/Yayın Bilgisi: (2009-10-01)

Correction: Host Genetic Factors and Vaccine-Induced Immunity to HBV Infection: Haplotype Analysis.
Yazar:: Kelli K. Ryckman, ve diğerleri
Baskı/Yayın Bilgisi: (2011-01-01)

KIR content genotypes associate with carriage of hepatitis B surface antigen, e antigen and HBV viral load in Gambians.
Yazar:: Louis-Marie Yindom, ve diğerleri
Baskı/Yayın Bilgisi: (2017-01-01)

mRNA Therapeutic Vaccine for Hepatitis B Demonstrates Immunogenicity and Efficacy in the AAV-HBV Mouse Model
Yazar:: Dorien De Pooter, ve diğerleri
Baskı/Yayın Bilgisi: (2024-02-01)

Coexisting patterns and significance of serum HBV RNA and HBV DNA in patients with treatment-naïve chronic hepatitis B virus infection
Yazar:: Kun-yan Hao, ve diğerleri
Baskı/Yayın Bilgisi: (2025-01-01)

Quantification of hepatitis B virus (HBV) DNA and HBV genotyping simultaneously in plasma using real-time polymerase chain reaction
Yazar:: Woottichai Khamduang, ve diğerleri
Baskı/Yayın Bilgisi: (2018-08-01)

Virological profiles of hepatitis B virus (HBV)-infected African patients treated with tenofovir
Yazar:: H.F. Njai, ve diğerleri
Baskı/Yayın Bilgisi: (2014-04-01)

A blind spot? Confronting the stigma of hepatitis B virus (HBV) infection - A systematic review
Yazar:: Mokaya, J, ve diğerleri
Baskı/Yayın Bilgisi: (2018)

Therapeutic effects of reduced glutathione on liver function, fibrosis, and HBV DNA clearance in chronic hepatitis B patients
Yazar:: Qiyao Wei, ve diğerleri
Baskı/Yayın Bilgisi: (2025-02-01)

Mechanisms of Hepatitis B Virus cccDNA and Minichromosome Formation and HBV Gene Transcription
Yazar:: Andoni Gómez-Moreno, ve diğerleri
Baskı/Yayın Bilgisi: (2024-04-01)

Efficacy and effectiveness of infant vaccination against chronic hepatitis B in the Gambia Hepatitis Intervention Study (1986-90) and in the nationwide immunisation program
Yazar:: Peto, T, ve diğerleri
Baskı/Yayın Bilgisi: (2014)

Generation of multivalent recombinant MVA vaccines for malaria
Yazar:: Orubu, T
Baskı/Yayın Bilgisi: (2012)

The impact of hepatitis B virus (HBV) splicing on HBV replication and disease progression
Yazar:: Laura C. McCoullough, ve diğerleri
Baskı/Yayın Bilgisi: (2024-08-01)

Clinical cancer chemoprevention: From the hepatitis B virus (HBV) vaccine to the human papillomavirus (HPV) vaccine
Yazar:: Horng-Jyh Tsai
Baskı/Yayın Bilgisi: (2015-04-01)